» Articles » PMID: 37436982

GRL-142 Binds to and Impairs HIV-1 Integrase Nuclear Localization Signal and Potently Suppresses Highly INSTI-resistant HIV-1 Variants

Abstract

Nuclear localization signal (NLS) of HIV-1 integrase (IN) is implicated in nuclear import of HIV-1 preintegration complex (PIC). Here, we established a multiclass drug-resistant HIV-1 variant (HIV) by consecutively exposing an HIV-1 variant to various antiretroviral agents including IN strand transfer inhibitors (INSTIs). HIV was extremely susceptible to a previously reported HIV-1 protease inhibitor, GRL-142, with IC of 130 femtomolar. When cells were exposed to HIV IN-containing recombinant HIV in the presence of GRL-142, significant decrease of unintegrated 2-LTR circular cDNA was observed, suggesting that nuclear import of PIC was severely compromised by GRL-142. X-ray crystallographic analyses revealed that GRL-142 interacts with NLS's putative sequence (DQAEHLK) and sterically blocks the nuclear transport of GRL-142-bound HIV's PIC. Highly INSTI-resistant HIV-1 variants isolated from heavily INSTI-experienced patients proved to be susceptible to GRL-142, suggesting that NLS-targeting agents would serve as salvage therapy agents for highly INSTI-resistant variant-harboring individuals. The data should offer a new modality to block HIV-1 infectivity and replication and shed light on developing NLS inhibitors for AIDS therapy.

Citing Articles

Strategies for the Viral Exploitation of Nuclear Pore Transport Pathways.

Zhang X, Lim K, Qiu Y, Hazawa M, Wong R Viruses. 2025; 17(2).

PMID: 40006906 PMC: 11860923. DOI: 10.3390/v17020151.


HIV-1 protease inhibitors and mechanisms of HIV-1's resistance.

Das D Glob Health Med. 2025; 6(6):357-362.

PMID: 39741988 PMC: 11680448. DOI: 10.35772/ghm.2024.01073.

References
1.
Oldenbuettel C, Wolf E, Ritter A, Noe S, Heldwein S, Pascucci R . Dolutegravir monotherapy as treatment de-escalation in HIV-infected adults with virological control: DoluMono cohort results. Antivir Ther. 2016; 22(2):169-172. DOI: 10.3851/IMP3082. View

2.
Gallay P, Hope T, Chin D, Trono D . HIV-1 infection of nondividing cells through the recognition of integrase by the importin/karyopherin pathway. Proc Natl Acad Sci U S A. 1997; 94(18):9825-30. PMC: 23276. DOI: 10.1073/pnas.94.18.9825. View

3.
Levin A, Armon-Omer A, Rosenbluh J, Melamed-Book N, Graessmann A, Waigmann E . Inhibition of HIV-1 integrase nuclear import and replication by a peptide bearing integrase putative nuclear localization signal. Retrovirology. 2009; 6:112. PMC: 3224947. DOI: 10.1186/1742-4690-6-112. View

4.
Aoki M, Chang S, Das D, Martyr C, Delino N, Takamatsu Y . A novel HIV-1 protease inhibitor, GRL-044, has potent activity against various HIV-1s with an extremely high genetic barrier to the emergence of HIV-1 drug resistance. Glob Health Med. 2020; 1(1):36-48. PMC: 7731189. DOI: 10.35772/ghm.2019.01003. View

5.
Koh Y, Aoki M, Danish M, Aoki-Ogata H, Amano M, Das D . Loss of protease dimerization inhibition activity of darunavir is associated with the acquisition of resistance to darunavir by HIV-1. J Virol. 2011; 85(19):10079-89. PMC: 3196396. DOI: 10.1128/JVI.05121-11. View